Literature DB >> 8473076

Analysis of hepatic recurrence of colorectal cancer after resection of hepatic metastases.

A Yamaguchi1, Y Kurosaka, M Kanno, Y Yonemura, R Izumi, K Miwa, I Miyazaki.   

Abstract

Forty patients with history of resected hepatic metastases of colorectal cancer were examined for pattern of recurrence. The 5-year survival rate was 41.3% for 40 patients. Recurrences of the malignancy were seen in 25 of the patients, with hepatic recurrence in 42.5% of them. The hepatic recurrence rate did not correlate with the lobar distribution of metastases or surgical methods. The pathological margins of less than 1 cm, 3 or more liver metastatic lesions, and the metastatic lesions of greater than 5 cm were at increased risk of hepatic recurrence. The recurrence rate was high, or 56% for aneuploid tumors, while it was 18.5% for diploid tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473076

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  4 in total

1.  Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate.

Authors:  Elie Oussoultzoglou; Philippe Bachellier; Edoardo Rosso; Radu Scurtu; Ioan Lucescu; Michel Greget; Daniel Jaeck
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Proposal of a new and simple staging system of colorectal liver metastasis.

Authors:  Ikuo Nagashima; Tadahiro Takada; Hirokazu Nagawa; Tetsuichiro Muto; Kota Okinaga
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

3.  Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors.

Authors:  Ikuo Nagashima; Tadahiro Takada; Miki Adachi; Hirokazu Nagawa; Tetsuichiro Muto; Kota Okinaga
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

4.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Authors:  Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.